130 related articles for article (PubMed ID: 25011934)
1. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
Geva R; Vecchione L; Kalogeras KT; Jensen BV; Lenz HJ; Yoshino T; Paez D; Montagut C; Souglakos J; Cappuzzo F; Cervantes A; Frattini M; Fountzilas G; Johansen JS; Høgdall EV; Zhang W; Yang D; Yamazaki K; Nishina T; Papamichael D; Vincenzi B; Macarulla T; Loupakis F; De Schutter J; Spindler KL; Pfeiffer P; Ciardiello F; Piessevaux H; Tejpar S
Gut; 2015 Jun; 64(6):921-8. PubMed ID: 25011934
[TBL] [Abstract][Full Text] [Related]
2. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
Ying HQ; Wang F; Chen XL; He BS; Pan YQ; Jie C; Liu X; Cao WJ; Peng HX; Lin K; Wang SK
Oncotarget; 2015 Sep; 6(29):28071-83. PubMed ID: 26363448
[TBL] [Abstract][Full Text] [Related]
3. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
4. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
5. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Kjersem JB; Skovlund E; Ikdahl T; Guren T; Kersten C; Dalsgaard AM; Yilmaz MK; Fokstuen T; Tveit KM; Kure EH
BMC Cancer; 2014 May; 14():340. PubMed ID: 24884501
[TBL] [Abstract][Full Text] [Related]
6. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
7. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Shepshelovich D; Townsend AR; Espin-Garcia O; Latifovic L; O'Callaghan CJ; Jonker DJ; Tu D; Chen E; Morgen E; Price TJ; Shapiro J; Siu LL; Kubo M; Dobrovic A; Ratain MJ; Xu W; Mushiroda T; Liu G
Cancer Med; 2018 Nov; 7(11):5478-5487. PubMed ID: 30318772
[TBL] [Abstract][Full Text] [Related]
8. Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
Liu G; Tu D; Lewis M; Cheng D; Sullivan LA; Chen Z; Morgen E; Simes J; Price TJ; Tebbutt NC; Shapiro JD; Jeffery GM; Mellor JD; Mikeska T; Virk S; Shepherd LE; Jonker DJ; O'Callaghan CJ; Zalcberg JR; Karapetis CS; Dobrovic A
Clin Cancer Res; 2016 May; 22(10):2435-44. PubMed ID: 27179112
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
Paez D; Paré L; Espinosa I; Salazar J; del Rio E; Barnadas A; Marcuello E; Baiget M
Cancer Sci; 2010 Sep; 101(9):2048-53. PubMed ID: 20550522
[TBL] [Abstract][Full Text] [Related]
10. FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer.
Inoue Y; Hazama S; Iwamoto S; Miyake Y; Matsuda C; Tsunedomi R; Okayama N; Hinoda Y; Yamasaki T; Suehiro Y; Yoshino S; Sakamoto J; Mishima H; Oka M
Mol Diagn Ther; 2014 Oct; 18(5):541-8. PubMed ID: 24828248
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
Park SJ; Hong YS; Lee JL; Ryu MH; Chang HM; Kim KP; Ahn YC; Na YS; Jin DH; Yu CS; Kim JC; Kang YK; Kim TW
Oncology; 2012; 82(2):83-9. PubMed ID: 22327884
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.
Dahan L; Norguet E; Etienne-Grimaldi MC; Formento JL; Gasmi M; Nanni I; Gaudart J; Garcia S; Ouafik L; Seitz JF; Milano G
BMC Cancer; 2011 Nov; 11():496. PubMed ID: 22117530
[TBL] [Abstract][Full Text] [Related]
13. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.
Rodríguez J; Zarate R; Bandres E; Boni V; Hernández A; Sola JJ; Honorato B; Bitarte N; García-Foncillas J
Eur J Cancer; 2012 Aug; 48(12):1774-80. PubMed ID: 22305465
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
15. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
Negri FV; Musolino A; Naldi N; Bortesi B; Missale G; Laccabue D; Zerbini A; Camisa R; Chernyschova N; Bisagni G; Loupakis F; Ruzzo A; Neri TM; Ardizzoni A
Pharmacogenomics J; 2014 Feb; 14(1):14-9. PubMed ID: 23296156
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.
Pantelic A; Markovic M; Pavlovic M; Jancic S
J BUON; 2016; 21(1):70-9. PubMed ID: 27061533
[TBL] [Abstract][Full Text] [Related]
17. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
18. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Brulé SY; Jonker DJ; Karapetis CS; O'Callaghan CJ; Moore MJ; Wong R; Tebbutt NC; Underhill C; Yip D; Zalcberg JR; Tu D; Goodwin RA
Eur J Cancer; 2015 Jul; 51(11):1405-14. PubMed ID: 25979833
[TBL] [Abstract][Full Text] [Related]
19. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
Zhang W; Azuma M; Lurje G; Gordon MA; Yang D; Pohl A; Ning Y; Bohanes P; Gerger A; Winder T; Hollywood E; Danenberg KD; Saltz L; Lenz HJ
Anticancer Res; 2010 Oct; 30(10):4209-17. PubMed ID: 21036743
[TBL] [Abstract][Full Text] [Related]
20. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer.
Augustine TA; Baig M; Sood A; Budagov T; Atzmon G; Mariadason JM; Aparo S; Maitra R; Goel S
Br J Cancer; 2015 Jan; 112(2):313-8. PubMed ID: 25412235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
